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Background
Diverse monogenic autoinflammatory diseases share
responsiveness to interleukin (IL)-1 blockade. This study
explored the utility of anakinra (an IL-1 receptor
antagonist) as a treatment option for clinically heteroge-
neous systemic inflammatory disease with autoinflam-
matory presentations where a genetic cause was not
defined.
Methods
A total of ten adult cases with ongoing inflammatory epi-
sodes, where alternative diagnoses, including malignancy
and infection, were evaluated. Genetic screening was also
performed to exclude known genetic causes of autoin-
flammatory disorders (e.g. cryopyrin-associated periodic
syndromes (CAPS), tumour necrosis factor receptor-
associated periodic syndrome (TRAPS), etc.)
Results
All patients had presentations that were atypical of recog-
nised autoinflammatory disorders and all were negative on
genetic screening. Eight of ten cases showed rapid respon-
siveness to anakinra with the ability to subsequently taper
alternative immunosuppression. Good responses to ana-
kinra were maintained with inadvertent drug discontinua-
tion being linked to disease flares.
Conclusions
The spectrum of poorly defined clinical and genetic autoin-
flammatory disorders that show responsiveness to anakinra
is considerable. In fact, responsiveness to anakinra appears
to be useful in diagnosis given the characteristically rapid
onset of efficacy and symptomatic improvement.
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